Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/65772
Title: One month of rifapentine plus isoniazid to prevent HIV-related Tuberculosis
Authors: Susan Swindells
Ritesh Ramchandani
Amita Gupta
Constance A. Benson
Jorge Leon-Cruz
Noluthando Mwelase
Marc A. Jean Juste
Javier R. Lama
Javier Valencia
Ayotunde Omoz-Oarhe
Khuanchai Supparatpinyo
Gaerolwe Masheto
Lerato Mohapi
Rodrigo O. Da Silva Escada
Sajeeda Mawlana
Peter Banda
Patrice Severe
James Hakim
Cecilia Kanyama
Deborah Langat
Laura Moran
Janet Andersen
Courtney V. Fletcher
Eric Nuermberger
Richard E. Chaisson
Keywords: Medicine
Issue Date: 14-Mar-2019
Abstract: © 2019 Massachusetts Medical Society. BACKGROUND Tuberculosis is the leading killer of patients with human immunodeficiency virus (HIV) infection. Preventive therapy is effective, but current regimens are limited by poor implementation and low completion rates. METHODS We conducted a randomized, open-label, phase 3 noninferiority trial comparing the efficacy and safety of a 1-month regimen of daily rifapentine plus isoniazid (1-month group) with 9 months of isoniazid alone (9-month group) in HIV-infected patients who were living in areas of high tuberculosis prevalence or who had evidence of latent tuberculosis infection. The primary end point was the first diagnosis of tuberculosis or death from tuberculosis or an unknown cause. Noninferiority would be shown if the upper limit of the 95% confidence interval for the between-group difference in the number of events per 100 person-years was less than 1.25. RESULTS A total of 3000 patients were enrolled and followed for a median of 3.3 years. Of these patients, 54% were women; the median CD4+ count was 470 cells per cubic millimeter, and half the patients were receiving antiretroviral therapy. The primary end point was reported in 32 of 1488 patients (2%) in the 1-month group and in 33 of 1498 (2%) in the 9-month group, for an incidence rate of 0.65 per 100 person-years and 0.67 per 100 person-years, respectively (rate difference in the 1-month group, −0.02 per 100 person-years; upper limit of the 95% confidence interval, 0.30). Serious adverse events occurred in 6% of the patients in the 1-month group and in 7% of those in the 9-month group (P=0.07). The percentage of treatment completion was significantly higher in the 1-month group than in the 9-month group (97% vs. 90%, P<0.001). CONCLUSIONS A 1-month regimen of rifapentine plus isoniazid was noninferior to 9 months of isoniazid alone for preventing tuberculosis in HIV-infected patients. The percentage of patients who completed treatment was significantly higher in the 1-month group.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85062854667&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/65772
ISSN: 15334406
00284793
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.